- Home
- BJRI vs ELVN Comparison
BJRI vs ELVN Comparison
Compare BJRI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- ELVN
- Stock Information
- Founded
- BJRI 1978
- ELVN 2016
- Country
- BJRI United States
- ELVN United States
- Employees
- BJRI N/A
- ELVN N/A
- Industry
- BJRI Restaurants
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- ELVN Health Care
- Exchange
- BJRI Nasdaq
- ELVN Nasdaq
- Market Cap
- BJRI 856.1M
- ELVN 927.8M
- IPO Year
- BJRI 1996
- ELVN 2020
- Fundamental
- Price
- BJRI $45.51
- ELVN $19.14
- Analyst Decision
- BJRI Hold
- ELVN Strong Buy
- Analyst Count
- BJRI 5
- ELVN 4
- Target Price
- BJRI $38.25
- ELVN $37.25
- AVG Volume (30 Days)
- BJRI 524.9K
- ELVN 361.5K
- Earning Date
- BJRI 07-24-2025
- ELVN 05-14-2025
- Dividend Yield
- BJRI N/A
- ELVN N/A
- EPS Growth
- BJRI N/A
- ELVN N/A
- EPS
- BJRI 0.95
- ELVN N/A
- Revenue
- BJRI $1,367,941,000.00
- ELVN N/A
- Revenue This Year
- BJRI $5.58
- ELVN N/A
- Revenue Next Year
- BJRI $3.00
- ELVN N/A
- P/E Ratio
- BJRI $46.84
- ELVN N/A
- Revenue Growth
- BJRI 2.91
- ELVN N/A
- 52 Week Low
- BJRI $27.61
- ELVN $13.30
- 52 Week High
- BJRI $45.62
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- BJRI 72.02
- ELVN 57.11
- Support Level
- BJRI $40.71
- ELVN $15.81
- Resistance Level
- BJRI $45.62
- ELVN $17.54
- Average True Range (ATR)
- BJRI 1.51
- ELVN 1.34
- MACD
- BJRI 0.07
- ELVN 0.11
- Stochastic Oscillator
- BJRI 97.76
- ELVN 64.66
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.